Zdrowie i gospodarka · 13/04/2011

FDA Expands Flexibility in Biologics Regulations

The FDA is amending its biologics regulations to allow for more flexibility in approving exceptions or alternatives to the existing constituent materials rule, enabling manufacturers to adopt advances in science and technology while maintaining public health protections.